{"nctId":"NCT04673786","briefTitle":"A Study to Compare the Efficacy and Safety of CT-P43 to Stelara in Patients With Plaque Psoriasis","startDateStruct":{"date":"2021-01-11","type":"ACTUAL"},"conditions":["Psoriasis"],"count":509,"armGroups":[{"label":"CT-P43","type":"EXPERIMENTAL","interventionNames":["Biological: CT-P43"]},{"label":"Stelara","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: CT-P43","Biological: Stelara"]}],"interventions":[{"name":"CT-P43","otherNames":[]},{"name":"Stelara","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n\\- Patient has had diagnosis of plaque-type psoriasis for at least 24 weeks.\n\nExclusion Criteria:\n\n* Patients diagnosed with forms of psoriasis other than plaque-type.\n* Patients previously received ustekinumab or a biosimilar of ustekinumab.\n* Patient who has allergies to the active substance or any of the excipients of ustekinumab or study drug, or patients with a hypersensitivity to immunoglobulin products or natural rubber and latex.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Mean Percent Improvement From Baseline in PASI Score at Week 12","description":"The percent improvement from baseline in Psoriasis Area and Severity Index (PASI) score at Week 12. PASI score can range from 0 (no psoriasis) to 72 (severe psoriasis).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.93","spread":"1.771"},{"groupId":"OG001","value":"75.89","spread":"1.739"}]}]}]},{"type":"SECONDARY","title":"The PASI Scores at Week 12","description":"The Psoriasis Area and Severity Index (PASI) score at Week 12. PASI score can range from 0 (no psoriasis) to 72 (severe psoriasis).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.98","spread":"3.412"},{"groupId":"OG001","value":"3.44","spread":"4.362"}]}]}]},{"type":"SECONDARY","title":"The Mean Percent Improvement From Baseline in PASI Score Through Week 52","description":"The percent improvement from baseline in Psoriasis Area and Severity Index (PASI) score through Week 52. PASI score can range from 0 (no psoriasis) to 72 (severe psoriasis).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93.79","spread":"11.794"},{"groupId":"OG001","value":"93.39","spread":"14.947"},{"groupId":"OG002","value":"91.58","spread":"13.264"}]}]}]},{"type":"SECONDARY","title":"The Number of Patients Achieving PASI 50, PASI 75, PASI 90, and PASI 100 Responses at Week 12","description":"The number of participants achieving at least 50%/75%/90%/100% improvement from baseline in Psoriasis Area and Severity Index (PASI) at Week 12. PASI score can range from 0 (no psoriasis) to 72 (severe psoriasis).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"247","spread":null},{"groupId":"OG001","value":"240","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"212","spread":null},{"groupId":"OG001","value":"187","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"129","spread":null},{"groupId":"OG001","value":"127","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"48","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Patients With sPGA Score of Clear (0) or Almost Clear (1) at Week 12","description":"The sPGA is a 5-point score ranging from 0 to 4, based on the physician's assessment of the erythema, average thickness, and scaling of all psoriatic lesions at a given time point. The sum of the 3 scales will be divided by 3 to obtain a final sPGA score.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"219","spread":null},{"groupId":"OG001","value":"201","spread":null}]}]}]},{"type":"SECONDARY","title":"The Change From Baseline in Dermatology Life Quality Index (DLQI) Through Week 52","description":"This DLQI is a 10-item patient-reported outcome questionnaire that, in addition to evaluating overall QoL, can be used to assess 6 different aspects that may affect QoL: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. Total scores range from 0 to 30 (less to more impairment).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.5","spread":"7.24"},{"groupId":"OG001","value":"-8.5","spread":"7.17"},{"groupId":"OG002","value":"-9.2","spread":"6.93"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":256},"commonTop":["COVID-19","Upper respiratory tract infection","Latent tuberculosis","Alanine aminotransferase increased","Aspartate aminotransferase increased"]}}}